Impax Laboratories Inc. (IPXL)

17.90
0.22 1.24
NYSE : Health Technology
Prev Close 17.68
Open 17.72
Day Low/High 17.50 / 18.29
52 Wk Low/High 13.47 / 18.29
Volume 839.29K
Avg Volume 916.90K
Exchange NYSE
Shares Outstanding 73.87M
Market Cap 1.35B
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Impax Laboratories Announces OxyContin® Patent Challenge Settlement

Impax Laboratories Announces OxyContin® Patent Challenge Settlement

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has entered into an agreement with Purdue Pharma L.

Ratings Changes Today

Upgrades: BMA, CIZN, ENTG, FBNC, FUR, HALL, IPXL, MG, RRMS, SYK, SYNL, UAMY, UVV Downgrades: GBR, SVT, TLK, WPX Initiations: ARCW, TSRE Read on to get TheStreet Quant Ratings' detailed report:

Short Interest Drops 28% For IPXL

Short Interest Drops 28% For IPXL

The most recent short interest data has been released by the NASDAQ for the 11/15/2013 settlement date, which shows a 608,131 share decrease in total short interest for Impax Laboratories Inc , to 1,569,391, a decrease of 27.93% since 10/31/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Impax Laboratories To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 3

Impax Laboratories To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 3

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Bryan M.

Impax Laboratories Launches Generic Solaraze® (Diclofenac Sodium Gel, 3%)

Impax Laboratories Launches Generic Solaraze® (Diclofenac Sodium Gel, 3%)

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it is commencing shipment of generic Solaraze® (diclofenac sodium gel, 3%), a first-to-file product, through Global Pharmaceuticals, Impax’s...

Insider Trading Alert - IPXL, IPI, DNKN, PMTC And LRN Traded By Insiders

Insider Trading Alert - IPXL, IPI, DNKN, PMTC And LRN Traded By Insiders

Stocks with insider trader activity include IPXL, IPI, DNKN, PMTC and LRN

Impax Laboratories To Present At The 2013 Credit Suisse Healthcare Conference On November 14

Impax Laboratories To Present At The 2013 Credit Suisse Healthcare Conference On November 14

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Credit Suisse Healthcare Conference on Thursday, November 14, at 9:30 a.

Impax Laboratories Reports Third Quarter 2013 Results

Impax Laboratories Reports Third Quarter 2013 Results

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported third quarter 2013 adjusted net income of $16.

Impax Laboratories And TOLMAR, Inc. Announce Final FDA Approval For Generic Solaraze® Gel (Diclofenac Sodium-3%)

Impax Laboratories And TOLMAR, Inc. Announce Final FDA Approval For Generic Solaraze® Gel (Diclofenac Sodium-3%)

Impax Laboratories, Inc. (NASDAQ: IPXL) and TOLMAR, Inc.

Impax Laboratories Confirms Patent Challenge Relating To Generic Atelvia® Delayed-Release Tablets, 35 Mg

Impax Laboratories Confirms Patent Challenge Relating To Generic Atelvia® Delayed-Release Tablets, 35 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with Atelvia® (Risedronate sodium) delayed-release tablets, 35 mg.

Impax Laboratories Schedules Conference Call And Webcast For Third Quarter 2013 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For Third Quarter 2013 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its third quarter 2013 financial results on Monday, November 4, 2013, after the close of the U.

Impax Laboratories Inc. Stock Downgraded (IPXL)

Impax Laboratories Inc. Stock Downgraded (IPXL)

Impax Laboratories (Nasdaq:IPXL) has been downgraded by TheStreet Ratings from from a buy to hold.

Ratings Changes Today

Upgrades: JW.A SKYW THOR ULTR VRNT Downgrades: ACPW AEY AMAP APU ARO CPWR DLR EVC FOR IPXL KRNY PDM TSLA TTEK Initiations: BLMN PSMI SAND Read on to get TheStreet Quant Ratings' detailed report:

5 Stocks Undervalued By Graham Number With Low Debt

5 Stocks Undervalued By Graham Number With Low Debt

James Dennin, Kapitall: The Graham Number is a great way to evaluate small-to-middle cap stocks, especially ones that you are concerned might be [...]

Impax Laboratories To Present At The Canaccord Genuity Annual Growth Conference

Impax Laboratories To Present At The Canaccord Genuity Annual Growth Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Canaccord Genuity Annual Growth Conference on Thursday, August 15, at 2:00 p.

Impax Laboratories Reports Second Quarter 2013 Results

Impax Laboratories Reports Second Quarter 2013 Results

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported second quarter 2013 adjusted earnings per diluted share of $0.

Ratings Changes To Be Publicly Issued on 7/31/13

Upgrades: AGM, CMC, DCM, ECA, ENV, EVOL, GAI, HLIT, IPXL, PEB, SENEB, SNSS, VLY, WLFC Downgrades: CMP, DMD, ERJ, FEIM, FIRE, GG, HFBC, HTCH, ICA, KTEC, MFNC, NVEC Initiations: EQM, EXA, NOW Read on to get TheStreet Quant Ratings' detailed report:

Impax Laboratories Launches Authorized Generic TRILIPIX® Delayed Release Capsules, 45 Mg And 135 Mg

Impax Laboratories Launches Authorized Generic TRILIPIX® Delayed Release Capsules, 45 Mg And 135 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it is commencing shipment of authorized generic TRILIPIX® (fenofibric acid) delayed release capsules, 45 mg and 135 mg, through Global...

Impax Laboratories Schedules Conference Call And Webcast For Second Quarter 2013 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For Second Quarter 2013 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its second quarter 2013 financial results on Thursday, August 8, 2013, after the close of the U.

Mary K. Pendergast Appointed To Impax Laboratories Board Of Directors

Mary K. Pendergast Appointed To Impax Laboratories Board Of Directors

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Mary K.

Impax Laboratories Confirms Patent Challenge Relating To Generic TOVIAZ® 4 Mg And 8 Mg

Impax Laboratories Confirms Patent Challenge Relating To Generic TOVIAZ® 4 Mg And 8 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with TOVIAZ® (fesoterodine fumarate extended-release tablets, 4 mg...

IPXL Makes Bullish Cross Above Critical Moving Average

IPXL Makes Bullish Cross Above Critical Moving Average

In trading on Monday, shares of Impax Laboratories Inc crossed above their 200 day moving average of $20.03, changing hands as high as $20.42 per share. Impax Laboratories Inc shares are currently trading up about 0.9% on the day.

5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks look poised to break out and trade higher from current levels.

Dr. Larry Hsu, Impax Laboratories President And Chief Executive Officer, To Retire

Dr. Larry Hsu, Impax Laboratories President And Chief Executive Officer, To Retire

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Dr.

Impax Laboratories Inc. Stock Downgraded (IPXL)

Impax Laboratories Inc. Stock Downgraded (IPXL)

Impax Laboratories (Nasdaq:IPXL) has been downgraded by TheStreet Ratings from from a buy to hold.

3 Stocks Spiking on Big Volume

3 Stocks Spiking on Big Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Impax Pharmaceuticals Announces Presentation Of RYTARYTM (IPX066) (Carbidopa And Levodopa) Extended-Release Capsules Phase III And Open-Label Extension Data At The American Academy Of Neurology 2013 Annual Meeting

Impax Pharmaceuticals Announces Presentation Of RYTARYTM (IPX066) (Carbidopa And Levodopa) Extended-Release Capsules Phase III And Open-Label Extension Data At The American Academy Of Neurology 2013 Annual Meeting

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced the presentation of results from its RYTARY TM (IPX066) Phase III and open-label extension trials at the 65 th Annual...

RYTARYTM (IPX066) (Carbidopa And Levodopa) Extended-Release Capsules Phase III And Open-Label Extension Data To Be Presented At The American Academy Of Neurology Conference

RYTARYTM (IPX066) (Carbidopa And Levodopa) Extended-Release Capsules Phase III And Open-Label Extension Data To Be Presented At The American Academy Of Neurology Conference

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that data from the RYTARY TM Phase III and open-label extension trials will be presented at the 65th Annual Meeting of the...

Impax Laboratories Shareholder Alert: Briscoe Law And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Impax Laboratories Shareholder Alert: Briscoe Law And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce an investigation into...

The 5 Dumbest Things on Wall Street: March 8

The 5 Dumbest Things on Wall Street: March 8

Here is this week's roundup of the dumbest actions on Wall Street.